glp-1 receptor agonist and dpp-4 inhibitor combination not recommended agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal ⚠️ Did you know? Akkermansia Bundle:6 Month Supply

glp-1 receptor agonist and dpp-4 inhibitor combination not recommended agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal ⚠️ Did you know? Akkermansia Bundle:6 Month Supply

⚠️ Did you know? Some patients have reported experiencing leg weakness or symptoms resembling drop foot after starting GLP-1 agonists like Ozempic, Wegovy, or similar medications. This can also happen after weight

#GLP1 #Cardiometabolic #EvidenceBasedMedicine To view or add a comment, sign in Attralus’ Zamubafusp Alfa Gets FDA Fast Track for AL Amyloidosis Attralus has received FDA Fast Track designation for zamubafusp alfa (AT-02) in immunoglobulin light-chain (AL) amyloidosis, advancing an investigational approach designed to address one of the major unmet needs in the disease: removal of established amyloid deposits

Akkermansia

Bundle:6 Month Supply

How much weight can I lose with GLP-1 treatment